CILOXAN SOLUTION

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE)

Disponibbli minn:

NOVARTIS PHARMACEUTICALS CANADA INC

Kodiċi ATC:

S03AA07

INN (Isem Internazzjonali):

CIPROFLOXACIN

Dożaġġ:

0.3%

Għamla farmaċewtika:

SOLUTION

Kompożizzjoni:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 0.3%

Rotta amministrattiva:

OPHTHALMIC

Unitajiet fil-pakkett:

5ML/10ML

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

ANTIBACTERIALS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0123207004; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2017-04-03

Karatteristiċi tal-prodott

_CILOXAN_
_®_
_ Product Monograph _
_ _
1
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
CILOXAN
®
Ciprofloxacin Ophthalmic Solution, USP
0.3% w/v (as ciprofloxacin hydrochloride)
Antibacterial Agent
and
Pr
CILOXAN
®
Ciprofloxacin Ophthalmic Ointment, USP
0.3% w/w (as ciprofloxacin hydrochloride)
Antibacterial Agent
Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.
Dorval, Quebec
H9S 1A9
Date of Revision:
www.novartis.ca
May 22, 2018
Submission Control No.: 210590
CILOXAN and DROP-TAINER are registered trademarks.
_CILOXAN_
_®_
_ Product Monograph _
_ _
2
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND ADMINISTRATION
................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND STABILITY
..........................................................................................10
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................10
PART II: SCIENTIFIC INFORMATION
................................................................................11
DETAILED PHARMACOLOGY
.....................................................................................11
MICROBIOLOGY............